Safety and efficacy of YM155 in diffuse large B-cell lymphoma (DLBCL)

被引：0
|
作者：
Cheson, B. D.
Vose, J. M.
Bartlett, N. L.
Lopez, A.
Van der Jagt, R. H.
Tolcher, A. W.
Weisenburger, D. D.
Seiz, A. L.
Shamsili, S.
Keating, A. T.
机构：
[1] Georgetown Univ Hosp, Bethesda, MD USA
[2] Univ Nebraska Med Ctr, Omaha, NE USA
[3] Washington Univ, Siteman Canc Ctr, St Louis, MO USA
[4] Hosp Valle De Hebron, Barcelona, Spain
[5] Ottawa Reg Canc Ctr, Ottawa, ON K1Y 4K7, Canada
[6] Inst Drug Dev, San Antonio, TX USA
[7] Astellas Pharma US Inc, Deerfield, IL USA
[8] Astellas Pharma Europe BV, Leiderdorp, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8502
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Cell-of-origin is an important biomarker in diffuse large B-cell lymphoma (DLBCL)
    Farinha, P
    Bebb, G
    Siebert, R
    Horsman, D
    Connors, JM
    Gascoyne, RD
    MODERN PATHOLOGY, 2005, 18 : 229A - 229A
  • [32] Diffuse large B-cell lymphoma - Molecular heterogeneity of diffuse large B-cell lymphoma
    Gascoyne, RD
    HEMATOLOGY JOURNAL, 2004, 5 : S144 - S148
  • [33] ANALYSIS OF EFFICACY, PROGNOSIS AND SAFETY OF RITUXIMAB IN THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA
    Zhuang, Qiang
    Xiang, Lina
    Jin, Ting
    Jin, Zhenlin
    ACTA MEDICA MEDITERRANEA, 2020, 36 (02): : 983 - 988
  • [34] Primary prostatic lymphoma with components of both diffuse large B-cell lymphoma (DLBCL) and MALT lymphoma
    Petrakis, G.
    Koletsa, T.
    Karavasilis, V
    Rallis, G.
    Bobos, M.
    Karkavelas, G.
    Kostopoulos, I
    HIPPOKRATIA, 2012, 16 (01) : 86 - 89
  • [35] Immunoexpression of p65 in diffuse large B-cell lymphoma (DLBCL) is not a prognostic factor in DLBCL
    Cemerikic-Martinovic, V.
    Markovic, O.
    Marisavljevic, D.
    Drndarevic, N.
    Martinovic, T.
    VIRCHOWS ARCHIV, 2011, 459 : S30 - S31
  • [36] The Role of microRNA-155 as a Biomarker in Diffuse Large B-Cell Lymphoma
    Koumpis, Epameinondas
    Georgoulis, Vasileios
    Papathanasiou, Konstantina
    Papoudou-Bai, Alexandra
    Kanavaros, Panagiotis
    Kolettas, Evangelos
    Hatzimichael, Eleftheria
    BIOMEDICINES, 2024, 12 (12)
  • [37] MicroRNA-155 expression and outcome in diffuse large B-cell lymphoma
    Jung, Inkyung
    Aguiar, Ricardo C. T.
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 144 (01) : 138 - 140
  • [38] Feasibility and preliminary efficacy of R-CHOP-14 in patients with diffuse large B-Cell lymphoma (DLBCL).
    Halaas, JL
    Moskowitz, CH
    Noy, A
    Portlock, C
    Horwitz, S
    Straus, D
    O'Connor, O
    Yahalom, J
    Zelenetz, AD
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 578S - 578S
  • [39] Activity and safety of ibrutinib and durvalumab in patients with relapsed or refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL)
    Herrera, A.
    Goy, A.
    Mehta, A.
    Ramchandren, R.
    Pagel, J.
    Svoboda, J.
    Guan, S.
    Hill, J.
    Kwei, K.
    Liu, E.
    Phillips, T.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E17 - E18
  • [40] Are there Genetic Predispositions to Diffuse Large B-cell Lymphoma (DLBCL) in Systemic Lupus (SLE)?
    Bernatsky, Sasha
    Clarke, Ann
    Ramsey-Goldman, Rosalind
    Gaffney, Patrick
    Spinelli, John
    Wang, Sophia
    Vyse, Timothy
    JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 937 - 937
12345